Research Overview
Research on Suma root (commonly referring to Hebanthe eriantha) has been most concentrated in early-stage pharmacological screening, particularly in vitro cytotoxicity against cancer cell lines and basic antimicrobial testing. The cited work evaluates methanolic root extracts using standard assays (MTT for cell viability, disc diffusion and broth microdilution for antibacterial activity) and includes a simple organismal toxicity screen (Artemia salina). These approaches reflect a broader pattern typical of medicinal-plant research at an exploratory stage: identifying bioactivity signals in crude extracts and estimating potency and general toxicity.
The strongest evidence currently supports that methanolic extracts of H. eriantha root can reduce viability of certain cancer cell lines under laboratory conditions, with reported IC50 values in the tens to hundreds of µg/mL range (e.g., HCT116 and 4T1 after 72 h exposure). There is also evidence of antibacterial activity against select organisms (e.g., S. aureus and P. vulgaris) with MICs on the order of hundreds of µg/mL, alongside moderate general toxicity in the brine shrimp lethality assay. Collectively, these findings support the conclusion that Suma root extracts contain bioactive constituents with measurable cytotoxic and antimicrobial effects in vitro, but they do not yet establish therapeutic efficacy or safety in humans.
Key gaps requiring further research include: (1) chemical characterization and standardization (identification of active compounds, batch-to-batch consistency, and structure–activity relationships); (2) mechanistic studies to determine whether cytotoxicity reflects selective anticancer activity versus nonspecific toxicity, including comparisons to normal human cell types and evaluation of apoptosis, cell-cycle effects, and relevant molecular targets; and (3) translational work, including in vivo efficacy models, pharmacokinetics, and comprehensive toxicology. Clinical evidence is not addressed by the abstract and remains a major unmet need; well-designed animal studies and, ultimately, controlled human trials would be required to substantiate any medical claims and to define safe, effective dosing.
1. What conditions has Suma Root been studied for?
-
Cancer-related outcomes (in vitro): Cytotoxic (cell-killing) effects against cancer cell lines, specifically:
Human colon cancer cells (HCT116)
Mouse breast tumor cells (4T1)
-
Antibacterial activity (in vitro): Inhibition of bacterial growth, including:
Staphylococcus aureus
Proteus vulgaris
-
General toxicity screening (preclinical): Toxicity in a brine shrimp lethality assay (Artemia salina), commonly used as an early hazard screen.
2. Does it work in treating those conditions? Summarize the evidence.
-
Cancer: The abstract reports reduced viability of cancer cells after treatment with a methanolic root extract:
HCT116 (colon cancer): IC50 = 272.6 µg/mL at 72 hours
4T1 (mouse breast tumor): IC50 = 88.5 µg/mL at 72 hours
Interpretation: This supports in vitro cytotoxic activity, but it does not demonstrate that Suma Root treats cancer in humans (or even in animals), because cell-culture cytotoxicity does not account for absorption, metabolism, dosing feasibility, tumor targeting, or safety in living organisms.
-
Bacterial infections: The methanolic extract inhibited bacterial growth in lab testing:
Zones of inhibition: 17.5 mm against S. aureus and 16 mm against P. vulgaris
MICs reported: 500 µg/mL (for the organisms highlighted as most inhibited)
Interpretation: This indicates antibacterial activity in vitro, but it does not establish effectiveness for treating infections in humans (e.g., whether effective concentrations can be achieved safely in tissues, or how it compares to standard antibiotics).
-
Toxicity: The extract showed “moderate toxicity” in Artemia salina with LC50 = 589.4 µg/mL. This is not evidence of therapeutic benefit; it is an early safety signal that bioactive compounds may also have harmful effects.
3. What health benefits does it have?
-
Potential anticancer-related activity (preclinical): The extract decreased viability of colon cancer (HCT116) and breast tumor (4T1) cells in vitro (IC50 272.6 and 88.5 µg/mL at 72h, respectively). This suggests the root contains compounds with cytotoxic potential.
-
Potential antibacterial activity (preclinical): In vitro inhibition of S. aureus and P. vulgaris with reported inhibition zones (17.5 and 16 mm) and MICs of 500 µg/mL suggests possible antimicrobial constituents.
Important limitation: The abstract does not provide evidence of clinical benefits (human trials) or even animal disease-model outcomes; therefore, “benefits” here are limited to laboratory findings and should not be interpreted as proven health effects in people.
4. Does it have any downsides or side effects?
-
General toxicity signal (preclinical): The methanolic extract showed moderate toxicity in a brine shrimp assay (LC50 = 589.4 µg/mL). While not directly translatable to humans, it suggests the extract contains biologically active compounds that can be harmful at some concentrations.
-
Cytotoxicity implies potential risk to normal cells: The study assessed effects on “cancerous and normal cells,” but the abstract only reports IC50 values for cancer cell lines and does not provide selectivity data (i.e., whether normal cells were spared). Without selectivity, cytotoxic activity can indicate a risk of harming healthy cells.
-
Unknown human safety profile from this abstract: No human adverse events, dosing, drug interactions, pregnancy/lactation safety, or organ-toxicity outcomes are reported here.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
No pharmacogenomic findings are provided in the abstract. There is no information on how genetic variants (e.g., drug-metabolizing enzymes, transporters, or tumor mutations) influence response, effectiveness, or toxicity of Suma Root extracts.
Evidence status: Not studied / not reported in the provided abstract.
References
-
Antiproliferative assay of suma or Brazilian ginseng (Hebanthe eriantha) methanolic extract on HCT116 and 4T1 cancer cell lines,in vitrotoxicity onArtemia salinalarvae, and antibacterial activity
Samaneh Rahamouz-Haghighi, Ali Sharafi (2024)
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!